PRGOPerrigo Company plc

$1B

Q4 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.3B+20.9% YoY

Gross Profit

$513M40.0% margin

Operating Income

$159M12.4% margin

Net Income

$73M5.7% margin

EPS (Diluted)

$0.52

QoQ Revenue Growth

+4.2%

Cash Flow

Operating Cash Flow

$217M

Free Cash Flow

$184M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$11.6B

Total Liabilities

$5.5B

Stockholders' Equity

$6.2B

Cash & Equivalents

$679M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.3B	$1.1B	+20.9%
Gross Profit	$513M	$455M	+12.6%
Operating Income	$159M	-$419M	+137.9%
Net Income	$73M	-$2.6B	+102.8%

Revenue Segments

Consumer Self-Care Americas

$643M50%

Consumer Self-Care International

$374M29%

RX Pharmaceuticals

$261M20%

PRGO Q4 2017 Earnings — Perrigo Company plc Revenue & Financial Results | Market Cap Arena